MGNX - マクロジェニクス (MacroGenics Inc.) マクロジェニクス

 MGNXのチャート


 MGNXの企業情報

symbol MGNx
会社名 MacroGenics Inc (マクロジェニクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 マクロジェニックス(MacroGenics Inc.)は臨床段階のバイオ医薬品会社である。同社は癌と自己免疫疾患及び感染症の治療用のモノクローナル抗体ベースの治療薬の発見と開発を中心とする。同社は抗体ベースの技術プラットフォームを使用して、また他の生物医薬品企業と協力して治療薬候補を開発する。ヒトの臨床試験では、主に技術プラットフォームを使用して作成された各タイプの癌の治療薬として製品候補のパイプラインがある。臨床製品候補であるmargetuximabは、Fc最適化プラットフォームを使用して強化された。同社はまた、免疫調節タンパク質のB7ファミリーのタンパク質であるB7-H3を標的とするいくつかの製品候補を開発している。同社の製品候補には、enoblituzumabおよびMGD009、MGC018、MGD006(フロテツズマブ)、MGD007、MGD011(duvortuxizumab)、PF-06671008およびMGD010も含まれる。   マクロジェニクスは米国のバイオ医薬品企業。癌や自己免疫疾患の治療薬としてモノクロ―ナル抗体の開発を手掛ける。乳癌、食道癌、膀胱癌の治療薬Margetuximab、黒色腫、膠芽細胞腫、前立腺癌、乳癌などの治療薬MGA271や、血液癌の治療薬MGD006、結腸直腸癌の治療薬MGD007、1型糖尿病治療薬Teplizumabの開発を行う。   MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. 2. Its product pipeline includes Margetuximab, Flotetuzumab, Enoblituzumab, MGA012, MGD013, MGD019, MGD009, MGC018, and MGD007 for oncology; and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
本社所在地 9704 Medical Center Drive Rockville MD 20850 USA
代表者氏名 Paulo F. Costa パウロF.コスタ
代表者役職名 Independent Chairman of the Board
電話番号 +1 301-251-5172
設立年月日 36739
市場名 NASDAQ National Market System
ipoyear 2013年
従業員数 330人
url www.macrogenics.com
nasdaq_url https://www.nasdaq.com/symbol/mgnx
adr_tso
EBITDA EBITDA(百万ドル) -31.49200
終値(lastsale) 20.19
時価総額(marketcap) 852772803.15
時価総額 時価総額(百万ドル) 791.52860
売上高 売上高(百万ドル) 177.55100
企業価値(EV) 企業価値(EV)(百万ドル) 490.63460
当期純利益 当期純利益(百万ドル) -34.09600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 MacroGenics Inc revenues increased from $3.7M to $23.5M. Net loss increased 18% to $92.8M. Revenues reflect Revenue from collaborative agreements increase from $2.4M to $23.1M. Higher net loss reflects Research&development-Bal Val increase of 47% to $94M (expense) General and administrative - Balancing v increase of 34% to $16.5M (expense).

 MGNXのテクニカル分析


 MGNXのニュース

   MacroGenics EPS beats by $0.28, beats on revenue  2020/02/25 21:26:10 Seeking Alpha
MacroGenics (NASDAQ:MGNX): FY GAAP EPS of -$3.16 beats by $0.28. Revenue of $64.19M (+6.8% Y/Y) beats by $9.31M. Shares +0.02%. Press Release
   The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate  2019/11/22 13:18:08 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 21.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amgen, Inc. (NASDAQ: AMGN ) (raised full-year guidance following completion of Otezla purchase from Celgene) Antares Pharma Inc (NASDAQ: ATRS ) Arvinas Inc (NASDAQ: ARVN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) BIO-TECHNE Corp (NASDAQ: TECH ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Cue Biopharma Inc (NASDAQ: CUE ) Epizyme Inc (NASDAQ: EPZM ) Kamada Ltd. (NASDAQ: KMDA ) Kodiak Sciences Inc (NASDAQ: KOD ) Molecular Templates Inc (NASDAQ: MTEM ) Recro Pharma Inc (NASDAQ: REPH ) (completed spin-off of Baudax Bio in a bid to a become a pure play CDMO) Down In The Dumps (Biotech stocks that hit 52-week lows on Nov. 21.) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) (received European approval for its Rhokiinsa 0.02% for the reduction of elevated intraocular pressure) Affimed NV (NASDAQ: AFMD ) Anixa Biosciences Inc (NASDAQ: ANIX ) CareDx Inc (NASDAQ: CDNA ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Genprex Inc (NASDAQ: GNPX ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Interpace Biosciences Inc (NASDAQ: IDXG ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) (priced its previously announced common stock offering) Iterum Therapeutics PLC (NASDAQ: ITRM ) Jaguar Health Inc (NASDAQ: JAGX ) MacroGenics Inc (NASDAQ: MGNX ) Merrimack Pharmaceuticals Inc (NASDAQ: MACK ) Neon Therapeutics Inc (NASDAQ: NTGN ) (announced a changed focus and the elimination of 24% of workforce) Novavax, Inc. (NASDAQ: NVAX ) Nuvectra Corp (NASDAQ: NVTR ) Onconova Therapeutics …
   TUESDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm  2019/11/12 15:29:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $MGNX #MGNX--TUESDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc.
   DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against MacroGenics, Inc. and Encourages Investors to Contact the Firm  2019/11/06 23:00:00 PR Newswire
NEW YORK, Nov. 6, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the District of Maryland on behalf of all investors that purchased…
   MacroGenics (MGNX) Expected to Beat Earnings Estimates: Should You Buy?  2019/10/30 14:34:22 Zacks Investment Research
MacroGenics (MGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 マクロジェニクス MGNX MacroGenics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)